# Junta clínica — PT-pseudo_b9aa0df93f2a (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b9aa0df93f2a",
  "pid": "PT-pseudo_b9aa0df93f2a",
  "task": 1,
  "psa": 5.5,
  "age": 71,
  "months": 1,
  "pirads": "5",
  "psad": 0.12,
  "psav": 1.47,
  "psap": 3.8,
  "vol": 49.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8111057,
  "medhx": "Hypertension",
  "meds": "amlodipine, lisinopril, metoprolol",
  "notes": "PSA 5.5 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 49 mL. csPCa 0.81.",
  "pmhx": [
    "Hypertension"
  ],
  "allergies": [],
  "vitals": {
    "weight": "116 kg",
    "height": "175 cm",
    "bmi": "37.9",
    "bp": "149/83 mmHg",
    "hr": "65 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "04 Feb 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a 5.5 ng/mL prostate-specific antigen elevation alongside a prior positive biopsy result."
    },
    {
      "s": "History",
      "t": "A married, 71-year-old warehouse manager who lives alone with his spouse listed as the primary contact. Initial workup began in late 2023 after an elevated prostate-specific antigen was detected. He experiences moderate lower urinary tract symptoms, scoring 15 on the IPSS, mainly due to nocturia and a diminished urinary stream, while explicitly denying haematuria or pelvic discomfort. His medical background includes well-managed hypertension treated with amlodipine, lisinopril, and metoprolol, plus an arthroscopic knee procedure in his forties. He stays physically active by cycling roughly 30 kilometres three times weekly, drinks about two units of alcohol each week, and reports no tobacco use. A recent audiology visit identified mild age-related presbycusis, currently managed with hearing aids. He has voiced significant apprehension about invasive interventions and insists on detailed explanations of every potential step prior to providing consent."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The prostate is symmetrically enlarged, smooth, and firm, with no palpable nodules or asymmetries. General inspection is unremarkable. Blood pressure measures 149/83 mmHg with a regular heart rate of 65 beats per minute. Abdominal palpation shows no suprapubic tenderness or distended bladder. Peripheral lymphadenopathy and bone tenderness are absent."
    }
  ],
  "occupation": "warehouse manager",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Audiology — hearing test"
  ],
  "alcohol": "2 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 15/35 (moderate LUTS)",
  "admin": "Patient anxious about procedures — allocate extra consult time.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9aa0df93f2a
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 5.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 1.47 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 49.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8111057 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: amlodipine, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 5.5 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 49 mL. csPCa 0.81.

Vitals: weight 116 kg, height 175 cm, BMI 37.9, BP 149/83 mmHg, HR 65 bpm. Smoking: Non-smoker.

Chief complaint: Assessment of a 5.5 ng/mL prostate-specific antigen elevation alongside a prior positive biopsy result.

History: A married, 71-year-old warehouse manager who lives alone with his spouse listed as the primary contact. Initial workup began in late 2023 after an elevated prostate-specific antigen was detected. He experiences moderate lower urinary tract symptoms, scoring 15 on the IPSS, mainly due to nocturia and a diminished urinary stream, while explicitly denying haematuria or pelvic discomfort. His medical background includes well-managed hypertension treated with amlodipine, lisinopril, and metoprolol, plus an arthroscopic knee procedure in his forties. He stays physically active by cycling roughly 30 kilometres three times weekly, drinks about two units of alcohol each week, and reports no tobacco use. A recent audiology visit identified mild age-related presbycusis, currently managed with hearing aids. He has voiced significant apprehension about invasive interventions and insists on detailed explanations of every potential step prior to providing consent.

Physical examination: Normal DRE: The prostate is symmetrically enlarged, smooth, and firm, with no palpable nodules or asymmetries. General inspection is unremarkable. Blood pressure measures 149/83 mmHg with a regular heart rate of 65 beats per minute. Abdominal palpation shows no suprapubic tenderness or distended bladder. Peripheral lymphadenopathy and bone tenderness are absent.

Patient info: warehouse manager; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 2 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.49
  uncertainty  +/- 0.14 (95% CI 0.22-0.77); among patients it cannot tell apart the outcome was 1.00 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses the use of MRI and biopsy in relation to PI-RADS scores and PSA density. It states, "A PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" is not sufficiently informed by the guideline because it fails to account for the patient's PI-RADS 5 score and the prior positive biopsy result. The guideline suggests that a PI-RADS score of $\ge 3$ triggers a biopsy, and the classifier's bid ignores this high-risk imaging finding.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose shows a PI-RADS score of 5, which mandates consideration for biopsy according to the guideline.
Prior biopsy status - The prior biopsy was positive, which is a critical factor that the guideline requires consideration for in determining the next step.
PSA density - The PSA density is $0.12 \text{ ng/mL}^2$, which is relevant as the guideline links this to the decision-making matrix.
Prostate volume - The prostate volume is $49.0 \text{ mL}$, which is a variable that the guideline makes decisive in risk-based pathways.
The guideline requires that the decision be made based on the PI-RADS score and the prior biopsy status, which the current data alone does not resolve.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on reconciling the high PI-RADS score with the prior positive biopsy result, which the guideline suggests requires further consideration.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> To establish the mpMRI prose, including lesion characteristics and extension.
  psa_trend (get_psa_trend) -> To establish the PSA trend beyond the headline value.
  previous_notes (get_previous_notes) -> To establish the management context and prior plans.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose show regarding the lesion size, zone, and extraprostatic extension?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. family_history dropped: the reading urologist never opened it in this decision. Dropped 1 question(s) that asked for a value already printed on the panel: "How does the PSA density of 0.12 ng/mL² factor into the decision-making matrix?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose shows a PI-RADS 5 lesion in the left mid peripheral zone, approximately 12 mm in size, with restricted diffusion and early focal enhancement.
psa_trend
The PSA trend shows values of 1.5 ng/mL on Aug 2023, 1.2 ng/mL on May 2024, and 5.5 ng/mL on Feb 2025.
previous_notes
The previous notes indicate that a referral to the urology outpatient clinic was scheduled on 10 Feb 2024 due to escalating PSA values and a prior positive biopsy.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not specify which question regarding free-PSA fraction, infection or prostatitis explaining the PSA, or fitness for the procedure needed to be answered.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose shows a PI-RADS 5 lesion, which mandates consideration for biopsy according to the EAU guideline.
The PSA trend shows a clear upward trajectory, with the most recent value being 5.5 ng/mL.
AGAINST sampling this patient now
The prior biopsy was positive, which is a critical factor that the guideline requires consideration for in determining the next step.

WHERE THIS LEANS
The combination of a PI-RADS 5 score and a prior positive biopsy strongly supports proceeding with a biopsy to further characterize the disease.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology\_report, psa\_trend, and previous\_notes—have answered the moderator's question Q1 by stating the mpMRI prose shows a PI-RADS 5 lesion in the left mid peripheral zone, approximately 12 mm in size, with restricted diffusion and early focal enhancement.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-EAU's reasoning, which suggests biopsy is warranted due to the PI-RADS 5 score, whereas the EXPERT-CLASSIFIER suggested no biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose show regarding the lesion size, zone, and extraprostatic extension? Answered by REGISTRAR with the radiology\_report, showing a 12 mm lesion in the left mid peripheral zone with restricted diffusion and early focal enhancement.
Q2. What does the psa\_trend show regarding the PSA trend beyond the headline value? Answered by REGISTRAR with the psa\_trend, showing values of 1.5 ng/mL on Aug 2023, 1.2 ng/mL on May 2024, and 5.5 ng/mL on Feb 2025.
Q3. What does the previous\_notes show regarding the management context and prior plans? Answered by REGISTRAR with the previous\_notes, indicating a referral was scheduled due to escalating PSA values and a prior positive biopsy.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS score of 5, which mandates consideration for biopsy per the EAU guideline, and the prior positive biopsy result, which is a critical factor the guideline requires consideration for. The PSA trend is also relevant because it shows a clear upward trajectory. The guideline does not support the classifier's suggestion of "NO BIOPSY" because it fails to account for the PI-RADS 5 score.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy to further characterize the disease, leaning towards a firm recommendation based on the high-risk imaging finding and the prior positive diagnosis.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Despite the prior positive biopsy, the PI-RADS 5 score from the mpMRI and the clear upward PSA trend strongly support proceeding with a biopsy to further characterize the disease. The combination of high-risk imaging and evolving biochemical markers outweighs the prior diagnosis in this context. The room converged on the need for further tissue sampling to guide definitive management.

What carried weight: bx=decisive, age=important, psa=important, vol=important, psad=important, cspca=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
